Newsroom

[The Street] Retrophin Assailed for ‘Exorbitant’ Price Hike

Runaway drug pricing has become a recent hot topic, witnessed best by the media and political bashing of Gilead Sciences (GILD_) for the $1,000-per-day cost of its hepatitis C pill Sovaldi.

Read more

[The Boston Globe] New Genzyme drug comes at a high price

There are a lot of innovative therapies with encouraging prospects and eye-popping price tags in the news lately. All of them pose hard questions about the big commercial risks drug companies must take and the enormous pricing power of medicines that can help suffering patients.

Read more

[Des Moines Register] State paying for pricey pill to treat Hepatitis C

The state of Iowa has started paying $1,000 per pill for a new drug targeting hepatitis C, but officials don’t plan to buy the medication for every person who carries the virus and qualifies for public health care.

Read more

[Bloomberg] Gilead Close to Sending $84,000 Drug to Poor Countries

Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India,Indonesia, and Pakistan.

Read more